long term side effects of glp 1 Adverse GLP-1 Receptor Agonists 🌱 GLP‑1 Medications vs. Lifestyle

In the run-in period, all patients, regardless of whether we are randomized to receive lira or placebo later, were subject to a hypocaloric diet and exercise regime, without GLP-1 receptor agonist, with the duration of the period for each patient being the time required to lose 5% of their baseline body weight In the STEP trials (Table 1), designed to evaluate the efficacy and safety of semaglutide 2.4mg (subcutaneous, weekly) in patients with obesity, or excess weight (BMI 27kg/m2) with complications, weight loss of between 15% and 17% was achieved 68 weeks after starting treatment.7678 In one of the trials, weight loss of 10% was reported after 20 weeks of therapy

10.1124/jpet.114.220350 53 Heckman-StoddardB

Tiered Evidence: Tier 1 - what the trials actually show ObesityThe strongest evidence is in obesity

TNF- and Poly(I:C) induction of A20 and activation of NF-B signaling are independent of ABCF1 in human airway epithelial cells

There was no increased rate of adverse effects leading to discontinuation of treatment in GLP-1RA users compared with nonGLP-1RA users (112)